[go: up one dir, main page]

PE20070174A1 - Derivados heterociclicos fusionados como inhibidores de quinasa - Google Patents

Derivados heterociclicos fusionados como inhibidores de quinasa

Info

Publication number
PE20070174A1
PE20070174A1 PE2006000775A PE2006000775A PE20070174A1 PE 20070174 A1 PE20070174 A1 PE 20070174A1 PE 2006000775 A PE2006000775 A PE 2006000775A PE 2006000775 A PE2006000775 A PE 2006000775A PE 20070174 A1 PE20070174 A1 PE 20070174A1
Authority
PE
Peru
Prior art keywords
phenyl
pyrrolo
pyrimidin
chloro
urea
Prior art date
Application number
PE2006000775A
Other languages
English (en)
Inventor
Shinichi Imamura
Yuya Oguro
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of PE20070174A1 publication Critical patent/PE20070174A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A DERIVADOS PIRROLO[3,2-d]PIRIMIDINA Y PIRROLO[3,2-d]PIRIDINA DE FORMULA (I), EN DONDE A ES PIRROL; X ES CH OPCIONALMENTE SUSTITUIDO; Y ES CH OPCIONALMENTE SUSTITUIDO O N; Z ES GRUPO HIDROCARBONADO O HETEROCICLICO AMBOS DIVALENTE Y OPCIONALMENTE SUSTITUIDO; T ES UN ENLACE SIMPLE O ALQUILENO(C1-C3); U ES AMIDO, SULFONAMIDO, UREIDO, CARBAMOILO O TIOUREIDO OPCIONALMENTE SUSTITUIDOS. SON PREFERIDOS: N- {2-CLORO-4-[(5-METIL-5H-PIRROLO[3,2-d]PIRIMIDIN-4-IL)OXI]FENIL}-N'-[3-(TRIFLUOROMETIL)FENIL]UREA, N-{2-CLORO-4-[(5-METIL-5H-PIRROLO[3,2-d]PIRIMIDIN-4-IL)OXI]FENIL}-N'-[3-(TRIFLUOROMETOXI)FENIL]UREA, N-{2-CLORO-4-[(5-METIL-5H-PIRROLO[3,2-d]PIRIMIDIN-4-IL)OXI]FENIL}-N'-[4-(TRIFLUOROMETIL)FENIL]UREA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO DE PREPARACION. ESTOS COMPUESTOS SON INHIBIDORES DEL RECEPTOR DE FACTOR DE CRECIMIENTO ENDOTELIAL VASCULAR (VEGFR), Y LA SELECTIVIDAD POR EL RECEPTOR DE FACTOR DE CRECIMIENTO ENDOTELIAL VASCULAR 2 (VEGFR2, KDR, Flk-1) Y SON UTILES PARA EL TRATAMIENTO Y PREVENCION DEL CANCER
PE2006000775A 2005-07-05 2006-07-04 Derivados heterociclicos fusionados como inhibidores de quinasa PE20070174A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005196866 2005-07-05
JP2006054102 2006-02-28

Publications (1)

Publication Number Publication Date
PE20070174A1 true PE20070174A1 (es) 2007-03-12

Family

ID=37055938

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000775A PE20070174A1 (es) 2005-07-05 2006-07-04 Derivados heterociclicos fusionados como inhibidores de quinasa

Country Status (8)

Country Link
US (1) US20090137580A1 (es)
EP (1) EP1904498A1 (es)
JP (1) JP2009500295A (es)
AR (1) AR055071A1 (es)
PE (1) PE20070174A1 (es)
TW (1) TW200740820A (es)
UY (1) UY31674A1 (es)
WO (1) WO2007004749A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101378716B1 (ko) * 2005-05-20 2014-04-10 메틸진 인코포레이티드 Ｖｅｇｆ 수용체 및 ｈｇｆ 수용체 신호전달의 억제제
CN101296928B (zh) * 2005-10-28 2011-01-19 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
TW200730527A (en) * 2005-12-02 2007-08-16 Takeda Pharmaceuticals Co Fused heterocyclic compound
NZ551796A (en) * 2006-12-05 2009-07-31 Craig Robert Stuart Bump-resistant pin tumbler lock
EP2099444A4 (en) 2006-12-14 2012-11-07 Nps Pharma Inc USE OF D-SERIN DERIVATIVES FOR THE TREATMENT OF ANTIBODIES
WO2009026717A1 (en) 2007-08-29 2009-03-05 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
WO2009096435A1 (ja) * 2008-01-29 2009-08-06 Takeda Pharmaceutical Company Limited 縮合複素環誘導体およびその用途
NZ589336A (en) * 2008-03-05 2011-12-22 Methylgene Inc Pyridine derivatives as inhibitors of protein tyrosine kinase activity
WO2009136663A1 (en) 2008-05-08 2009-11-12 Takeda Pharmaceutical Company Limited Fused heterocyclic derivatives and use thereof
WO2010108503A1 (en) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion of neuronal integration in neural stem cell grafts
US9951008B2 (en) * 2009-11-03 2018-04-24 University Of Notre Dame Du Lac Ionic liquids comprising heteraromatic anions
NZ601788A (en) * 2010-03-01 2014-11-28 Myrexis Inc Inhibitors of nicotinamide phosphoribosyltransferase and therapeutic uses thereof
US8912184B1 (en) 2010-03-01 2014-12-16 Alzheimer's Institute Of America, Inc. Therapeutic and diagnostic methods
BR112012024705A2 (pt) 2010-03-31 2016-06-07 Actelion Pharmaceuticals Ltd derivados antibacterianos de isoquinolin-3-ilureia
WO2012008564A1 (ja) * 2010-07-16 2012-01-19 協和発酵キリン株式会社 含窒素芳香族複素環誘導体
AR088729A1 (es) 2011-03-29 2014-07-02 Actelion Pharmaceuticals Ltd Derivados de 3-ureidoisoquinolin-8-ilo y una composicion farmaceutica
RU2616500C2 (ru) * 2011-10-31 2017-04-17 Новартис Аг Композиция пазопаниба
DK2981535T3 (da) 2013-04-02 2021-03-01 Oxular Acquisitions Ltd Urinstofderivater, der er anvendelige som kinaseinhibitorer
LT3049417T (lt) 2013-07-31 2019-02-11 Merck Patent Gmbh Piridinai, pirimidnai ir pirazinai kaip btk inhibitoriai ir jų panaudojimas
US10385251B2 (en) 2013-09-30 2019-08-20 University Of Notre Dame Du Lac Compounds, complexes, compositions, methods and systems for heating and cooling
WO2015069799A1 (en) 2013-11-05 2015-05-14 University Of Notre Dame Du Lac Carbon dioxide capture using phase change ionic liquids
JP6514703B2 (ja) 2013-12-20 2019-05-15 トピバート ファーマ リミテッド キナーゼインヒビターとして有用な尿素誘導体
MA40775A (fr) 2014-10-01 2017-08-08 Respivert Ltd Dérivé d'acide 4-(4-(4-phényluréido-naphtalén -1-yl) oxy-pyridin-2-yl) amino-benzoïque utilisé en tant qu'inhibiteur de la kinase p38
US10280145B2 (en) 2015-08-31 2019-05-07 Toray Industries, Inc. Urea derivative and use therefor
MA44607A (fr) 2016-04-06 2021-05-19 Oxular Acquisitions Ltd Inhibiteurs de kinase
US10196378B2 (en) * 2016-08-25 2019-02-05 The Regents Of The University Of Michigan Inhibitors of BCR-ABL mutants and use thereof
CN109180677A (zh) * 2017-06-30 2019-01-11 厦门大学 取代芳基醚类化合物、其制备方法、药用组合物及其应用
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
CN110128299B (zh) * 2019-05-13 2020-11-10 浙江大学 一种二苯基脲类抗肿瘤小分子抑制剂及其制备方法
WO2020245208A1 (en) 2019-06-04 2020-12-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN116789670A (zh) * 2022-03-17 2023-09-22 中国科学院合肥物质科学研究院 一种选择性csf1r抑制剂及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
AR004010A1 (es) * 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
TR199900048T2 (xx) * 1996-07-13 1999-04-21 Glaxo Group Limited Protein tirozin kinaz inhibit�rleri olarak bisiklik heteroaromatik bile�ikler
EP0923582B1 (en) 1996-08-28 2006-09-20 Pfizer Inc. Substituted 6,5-hetero-bicyclic derivatives
ATE253051T1 (de) * 1999-01-22 2003-11-15 Kirin Brewery Chinolinderivate und chinazolinderivate
WO2001083456A1 (en) 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Condensed heteroaryl derivatives
WO2002032872A1 (fr) * 2000-10-20 2002-04-25 Eisai Co., Ltd. Composes a noyau aromatique azote
PL209822B1 (pl) * 2001-04-27 2011-10-31 Kirin Pharma Kk Pochodna chinoliny lub chinazoliny, zawierająca ją kompozycja farmaceutyczna i zastosowanie
MEP8409A (en) * 2004-06-02 2011-12-20 Fused heterocyclic compound

Also Published As

Publication number Publication date
AR055071A1 (es) 2007-08-01
WO2007004749A1 (en) 2007-01-11
JP2009500295A (ja) 2009-01-08
US20090137580A1 (en) 2009-05-28
TW200740820A (en) 2007-11-01
UY31674A1 (es) 2009-08-31
EP1904498A1 (en) 2008-04-02

Similar Documents

Publication Publication Date Title
PE20070174A1 (es) Derivados heterociclicos fusionados como inhibidores de quinasa
RU2538200C2 (ru) ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ (ВАРИАНТЫ), СПОСОБ ИХ ПОЛУЧЕНИЯ, КОМПОЗИЦИЯ ИХ СОДЕРЖАЩАЯ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С КИНАЗОЙ mTOR ИЛИ КИНАЗОЙ PI3K
ES2344347T3 (es) Derivados de cianopiridina novedosos utiles en el tratamiento de cancer y otros trastornos.
PE20080538A1 (es) Derivado heterociclico fusionado y su uso
PE20121127A1 (es) Derivados de piridina y pirazina como moduladores de cinasa de proteina
CA2900308C (en) Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
PE20040189A1 (es) Pirimidina y piridina biciclicos como inhibidores de p38 quinasa
AR079231A1 (es) Derivados de imidazoquinolina
PE20050157A1 (es) Derivados de n-acil nitrogeno heterociclicos como ligandos del receptor activador del proliferador de peroxisoma (ppar)
PE20060932A1 (es) Derivados de sulfonamidas como moduladores de receptores de glucocorticoides (gr)
RU2012143689A (ru) Спироциклические соединения и их применение в качестве терапевтических агентов и диагностических зондов
PE20130311A1 (es) Composiciones y metodos para modular la via de senalizacion de wnt
PE20100087A1 (es) Compuestos y composiciones como inhibidores de cinasa
PE20170774A1 (es) Compuestos de indazol como inhibidores de cinasa fgfr, preparacion y uso de los mismos
PE20071223A1 (es) Procedimiento de preparacion de derivados de acil-amino-alquilen-amida
AR074426A1 (es) Compuesto de n-(((1s,4s,6s)-3-(2-piridinilcarbonil)3-azabiciclo (4,1.0)hept-4-il) metil)-2-heteroarilamina, su uso para la prepracion de un medicamento para el tratamiento de una enfermedad que requiere un antagonista de un receptor de orexina humana y composicion farmaceutica que lo comprende
AR058403A1 (es) PIRIMIDINILOXI Y PIRIDINILOXI UREAS SUSTITUíDAS COMO INHIBIDORES DE PROTEíNA QUINASAS, COMPOSICIONES FARMACÉUTICAS QUE LAS CONTIENEN Y SU USO EN LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR LA ACTIVIDAD BASAL DE B-RAF.
NO20083822L (no) Farmasoytisk antikreftpreparat
PE20070855A1 (es) Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
PE20180177A1 (es) Derivados de 1-(het) arilsulfonil-(pirrolidin o piperidin)-2-carboxamida y su uso como antagonistas de trpa1
RU2013109132A (ru) Химические соединения
AR054360A1 (es) Derivados de tiazol como herbicidas
NO330563B1 (no) Substituerte benzazoler og deres anvendelse som medikament samt farmasoytiske sammensetninger
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
AR046394A1 (es) Derivados de quinolinas y quinazolinas, metodo de preparacion de los mismos y composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal